[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnosed-with-acromegaly-currently-in-the-active-stage-of-the-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnosed-with-acromegaly-currently-in-the-active-stage-of-the-disease":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100638047",false,"NCT07623824","A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly","A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly","Inclusion Criteria:\n\n* Male or female participants aged 18 to 80 years (including boundary values)\n* Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng\u002FmL and IGF-1 index ≥ 1.3; for patients who have undergone pituitary tumor surgery, fasting GH ≥ 2.5 ng\u002FmL and IGF-1 index ≥ 1.3)；\n\nExclusion Criteria:\n\n* Have received pituitary radiotherapy within the 5 years prior to screening\n* Have undergone major surgery (including pituitary surgery) within 6 months prior to screening or are expected to require surgery (including pituitary surgery) or radiotherapy during the study period\n* Within three months before the screening, participants received drugs such as long-acting lanretide, long-acting octreotide, pervesomone, and cabergoline, or traditional Chinese medicines for treating acromegaly. Receive bromocriptine within one month before screening; Received short-acting octreotide or lanretide short-acting preparations for treatment within 7 days before screening; Or have received any other investigational drug within 30 days before screening or within 5 half-lives (whichever is longer)\n* Previous failure to respond to octreotide or lantreotide monotherapy (defined as: after at least 3 months of treatment with octreotide microspheres ≥30 mg or lantreotide ≥120 mg, or after at least 3 months of treatment with parietide microspheres ≥40 mg, random GH ≥2.5 ng\u002FmL and\u002For IGF-1 index ≥1.3) or history of intolerance.\n* Participants with obvious visual field defects caused by optic chiasm compression and requiring surgical intervention\n* HbA1c\\>8.5%","ALL","18 Years","80 Years",{"count":19,"type":20},154,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.",[26],"Diagnosed With Acromegaly, Currently in the Active Stage of the Disease","NOT_YET_RECRUITING","2026-05-29",{"date":30,"type":31},"2026-06-03","ACTUAL",{"date":33,"type":20},"2026-05-31",{"date":35,"type":20},"2029-12-30",{"name":37,"class":38},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","INDUSTRY",""]